Author:
Mahasirimongkol Surakameth,Uppapong Ballang,Puangtubtim Wiroj,Dhepakson Panadda,Panyajai Parnuphan,Thawong Naphatcha,Pinyosukhee Nadthanan,Rojanawiwat Archawin,Wichukchinda Nuanjun,Soonthorncharttrawat Sakulrat,Larpardisorn Kanisorn,Amonyingcharoen Sumet,Juntaped Kritchai,Chaiyakum Tassanee,Tongkamsen Chayada,Srilaket Jeerapa,Chipatoom Jiratikamon,Wichajarn Rattanawadee,Chatchawankanpanich Nutchanat,Pattarapreeyakul Lapasrada,Chaiya Porntip,Mongkolsiri Kaveewan,Tuntigumthon Suthida,Sophondilok Kritsamon,Saengtong Nalinee,Jongpitisub Kodcharad,Sirilak Supakit
Abstract
Between the first case of COVID-19 in January 2020 and the end of 2021, Thailand experienced four waves of the epidemic. The third and fourth waves were caused by the alpha and delta strains from April 2021 to November 2021. Serosurveillance studies provide snapshots of the true scale of the outbreak, including the asymptomatic infections that could not be fully captured by a hospital-based case detection system. We aimed to investigate the distribution of SARs-CoV-2 seroprevalence in unvaccinated adults after the delta wave outbreak. From November to December 2021, we conducted a cross-sectional survey study in 12 public health areas (PHAs) across Thailand. A total of 26,717 blood samples were collected and tested for SARs-CoV-2 antibodies (anti-S IgG) using a qualitative immunoassay. The results showed that seropositive prevalence in this cohort was 1.4% (95% CI: 1.24 to 1.52). The lowest prevalence was in the northern region (PHA 1) and in central Thailand (PHA 3) at 0.4% (95% CI: 0.15 to 0.95), while the highest was in the southern region of Thailand (PHA 12) at 5.8% (95% CI: 4.48 to 7.29). This seropositive prevalence was strikingly lower than the reports from other countries. Our serosurveillance results suggest that the vaccination of unvaccinated groups should be accelerated, especially in the public health areas with the lowest seroprevalence.
Funder
the Department of Medical Science, Ministry of Public Health, Thailand
Subject
Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology
Reference21 articles.
1. COVID-19 (Coronavirus Disease 2019): A New Coronavirus Disease;Dousari;Infect. Drug Resist.,2020
2. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): A Global Pandemic and Treatment Strategies;Sharma;Int. J. Antimicrob. Agents,2020
3. (2022, July 05). World Health Organization WHO Coronavirus (COVID-19) Dashboard|WHO Coronavirus (COVID-19) Dashboard with Vaccination Data. Available online: https://covid19.who.int/.
4. Uansri, S., Tuangratananon, T., Phaiyarom, M., Rajatanavin, N., Suphanchaimat, R., and Jaruwanno, W. (2021). Predicted Impact of the Lockdown Measure in Response to Coronavirus Disease 2019 (COVID-19) in Greater Bangkok, Thailand, 2021. Int. J. Environ. Res. Public Health, 18.
5. Real-Time RT-PCR in COVID-19 Detection: Issues Affecting the Results;Tahamtan;Expert Rev. Mol. Diagn.,2020